1-(2,6-Dichloro-4-pyridyl)-3-((4-methyl-5-(1-methylpyrazol-4-yl)-2-pyridyl)amino)urea

ID: ALA4867313

PubChem CID: 164622777

Max Phase: Preclinical

Molecular Formula: C16H15Cl2N7O

Molecular Weight: 392.25

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)ncc1-c1cnn(C)c1

Standard InChI:  InChI=1S/C16H15Cl2N7O/c1-9-3-15(19-7-12(9)10-6-20-25(2)8-10)23-24-16(26)21-11-4-13(17)22-14(18)5-11/h3-8H,1-2H3,(H,19,23)(H2,21,22,24,26)

Standard InChI Key:  WXWNPQSQCBBZMR-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
   15.0941  -13.9873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0930  -14.8146    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8078  -15.2275    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.5243  -14.8141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5214  -13.9836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8060  -13.5745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.2393  -15.2255    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.9532  -14.8119    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.6683  -15.2233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3821  -14.8097    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.6695  -16.0483    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.8035  -12.7495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0972  -15.2210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0941  -16.0466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.8083  -16.4579    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5231  -16.0443    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.5192  -15.2151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.8043  -14.8075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.2315  -14.7990    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   20.8093  -17.2829    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   14.3796  -13.5749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2932  -12.7552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4861  -12.5839    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.0738  -13.2986    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.6260  -13.9114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2533  -13.3851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  9 11  2  0
  6 12  1  0
 10 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
 17 19  1  0
 15 20  1  0
  1 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  1  0
 25 21  2  0
 24 26  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4867313

    ---

Associated Targets(Human)

S1PR2 Tchem Sphingosine 1-phosphate receptor Edg-5 (1593 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 392.25Molecular Weight (Monoisotopic): 391.0715AlogP: 3.64#Rotatable Bonds: 4
Polar Surface Area: 96.76Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 11.88CX Basic pKa: 5.79CX LogP: 3.38CX LogD: 3.37
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.47Np Likeness Score: -2.02

References

1. Mammoliti O, Palisse A, Joannesse C, El Bkassiny S, Allart B, Jaunet A, Menet C, Coornaert B, Sonck K, Duys I, Clément-Lacroix P, Oste L, Borgonovi M, Wakselman E, Christophe T, Houvenaghel N, Jans M, Heckmann B, Sanière L, Brys R..  (2021)  Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis.,  64  (9.0): [PMID:33939425] [10.1021/acs.jmedchem.1c00138]
2. Osada, Makoto M, Yatomi, Yutaka Y, Ohmori, Tsukasa T, Ikeda, Hitoshi H and Ozaki, Yukio Y.  2002-12-06  Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist.  [PMID:12445827]
3. Sanna, M Germana MG and 10 more authors.  2004-04-02  Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.  [PMID:14732717]
4. Deng, Hongfeng H and 6 more authors.  2013-10-10  Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.  [PMID:24900589]
5. Demont, Emmanuel H EH and 22 more authors.  2016-02-11  Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.  [PMID:26751273]
6. Scott, F L FL and 12 more authors.  2016-06  Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.  [PMID:26990079]

Source